AVPR1A agonists(Vasopressin V1a receptor agonists), AVPR1B agonists(Vasopressin V1b receptor agonists), AVPR2 agonists(Vasopressin V2 receptor agonists)

Therapeutic Areas

Digestive System DisordersUrogenital DiseasesOther Diseases

Active Indication

Bleeding esophageal varicesHepatorenal SyndromeHemorrhage+ [1]

Inactive Indication

AscitesDecompensated cirrhosis of liverFibrosis+ [1]

Originator Organization

Mallinckrodt Pharmaceuticals Ireland Ltd.

Active Organization

Ferring GmbH

BioVie, Inc.Ferring Pharmaceuticals Pty Ltd.

+ [1]

Inactive Organization

Ferring Pharmaceuticals A/S

Keenova Therapeutics Plc

License Organization

Ferring Holding SA

Zhejiang Medical Technology Development Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

Australia (14 May 2012),

Bleeding esophageal varicesHepatorenal Syndrome

RegulationOrphan Drug (United States), Fast Track (United States)

Structure/Sequence

Molecular FormulaC54H78N16O17S2

InChIKeyBYDVFOPTAIPAGA-LCGYVTRFSA-N

CAS Registry914453-96-6

Sequence Code 440876

Source: *****

131

Clinical Trials associated with Terlipressin Acetate

NCT07304466

/ Not yet recruitingNot ApplicableIIT

Comparison of the Effects of Terlipressin and Somatostatin on Portal Pressure in Patients Undergoing Living Donor Liver Transplantation

The goal of this clinical trial is to compare the effects of somatostatin and terlipressin on lowering portal pressure in patients with portal hypertension undergoing liver transplantation, and to investigate whether there are differences in clinical outcomes between the two drugs. The study will evaluate the decrease in portal pressure from baseline following drug administration at defined time points. It will also compare the effects of these drugs on hemodynamics, bleeding, and transfusion requirements. After baseline intraoperative direct portal pressure measurement, a bolus dose of the study drug will be administered, followed by continuous intravenous infusion intraoperatively and for 24 hours postoperatively. Direct portal pressure will be measured again 5 minutes after the bolus dose, after the portal vein anastomosis, after the hepatic artery anastomosis, and, if performed after splenic artery ligation. Hemodynamic parameters will be recorded, and the drugs will be compared in terms of their intraoperative hemodynamic effects. As elevated portal pressure is associated with increased bleeding, intraoperative blood loss and transfusion needs will also be assessed between the groups. Patients will be followed for 7 days postoperatively for clinical and laboratory outcomes.

Start Date29 Dec 2025

Sponsor / Collaborator

Istanbul Medipol University

NCT07252401

/ Not yet recruitingNot ApplicableIIT

Terlipressin vs. Somatostatin in Cirrhotic Patients With Acute Gastrointestinal Bleeding and Acute Kidney Injury: A Multicenter Randomized Controlled Trial

Acute gastrointestinal bleeding (AGIB) is a common complication in the decompensated stage of liver cirrhosis, of which approximately 70% is acute variceal bleeding (AVB) caused by portal hypertension. Existing evidence suggests that both terlipressin and somatostatin can be used to control AVB in cirrhotic patients, but terlipressin may be the first-line treatment for cirrhotic patients with AGIB complicated by acute kidney injury (AKI). Herein, a multicenter randomized controlled trial (RCT) has been designed to compare the efficacy of terlipressin and somatostatin in the treatment of cirrhotic patients with AGIB complicated by AKI.

Start Date25 Dec 2025

Sponsor / Collaborator

The General Hospital of Shenyang Military Region

CTRI/2025/08/092559

/ RecruitingNot Applicable

Effect of low-dose Terlipressin with Albumin on Major Adverse Kidney Events in patients with Septic Shock: A Randomised Controlled Trial - NIL

Start Date18 Aug 2025

Sponsor / Collaborator-

100 Clinical Results associated with Terlipressin Acetate

100 Translational Medicine associated with Terlipressin Acetate

100 Patents (Medical) associated with Terlipressin Acetate

1,278

Literatures (Medical) associated with Terlipressin Acetate

01 Mar 2026·CRITICAL CARE MEDICINE

Vasoactive Medications and the Microcirculation in Septic Shock: A Scoping Review

Article

Author: Sachar, Saloni ; Nero, Neil ; Siuba, Matthew T. ; Tonelli, Adriano R. ; Berro, Jana ; Bauer, Seth R. ; Hamzaoui, Olfa ; Sathianathan, Shyama

Objectives::

To summarize knowledge and identify gaps in evidence regarding the effects of vasoactive medications on microvascular perfusion in septic shock.

Data Sources::

We conducted a comprehensive search of MEDLINE, Embase, and the Cochrane Central Register of Controlled Trials.

Study Selection::

Studies included adult patients with septic shock who received vasoactive therapy with corresponding microcirculatory measurements between 1946 and May 7, 2025.

Data Extraction::

Data extraction was performed in Covidence by two independent reviewers. Data items included study design, patient population, vasoactive medication, macrohemodynamics, and microcirculation measurements and techniques.

Data Synthesis::

Thirty-three studies were included evaluating several vasoactive medications and microvascular measurement techniques. Despite heterogeneous study design, studies that recruited patients within 24 hours tended to report more significant microcirculatory changes. Microcirculatory changes and cardiac index only aligned in 39% of cases, highlighting a disconnect between global hemodynamics and microvascular perfusion. Several vasoactives, including norepinephrine, vasopressin, terlipressin, and levosimendan demonstrated context-dependent improvements in peripheral/sublingual microcirculation. Despite limitations in directly monitoring gastric microcirculation, dobutamine may enhance perfusion; however, further studies are needed to support dobutamine and other vasoactive agents’ impacts on clinical outcomes.

Conclusions::

Despite growing interest in perfusion-guided care, significant challenges remain in understanding how vasoactive agents affect the microcirculation. Clarifying these effects through standardized research and point-of-care perfusion monitoring remains a challenge in advancing outcome-driven resuscitation strategies.

20 Feb 2026·MEDICINE

Development and validation of a bedside nomogram for predicting 30-day mortality in patients with type 1 hepatorenal syndrome: A retrospective cohort study

Article

Author: Shen, Yining ; Hu, Yanqing ; Zhong, Yandan ; Jiang, Chunling ; Fan, Fan

Type 1 hepatorenal syndrome (T1HRS) is the most rapidly progressive form of functional renal failure in decompensated cirrhosis, with 30-day mortality exceeding 50%. We aimed to develop and internally validate a bedside nomogram to predict 30-day death in intensive care unit (ICU) patients with T1HRS. Using the Medical Information Mart for Intensive Care IV database, adults who met diagnostic criteria for T1HRS within 48 hours of ICU admission (2008–2019) were randomly split 7:3 into development (n = 340) and internal validation (n = 146) sets. Predictors collected within 24 hours of diagnosis were selected using least absolute shrinkage and selection operator-Cox; a multivariable Cox model was constructed and internally validated. Performance was assessed by area under the curve, calibration slope, and decision-curve analysis. Overall 30-day mortality was 47.1% (229/486). Seven variables were retained: model for end-stage liver disease-sodium, total bilirubin, international normalized ratio, serum creatinine, mean arterial pressure, urine Na + , and terlipressin use. The model achieved the area under the curves of 0.82 (development) and 0.81 (validation) at 30 days, with a calibration slope of 0.99. The findings were robust to competing-risk, terlipressin exclusion, and Child–Pugh substitution. A 7-variable nomogram provides accurate, well-calibrated, and clinically actionable prediction of 30-day mortality in ICU patients with T1HRS, ready for prospective evaluation and trial stratification.

04 Feb 2026·Cureus Journal of Medical Science

Upper Gastrointestinal Bleeding Due to Ruptured Gastric Varices: A Diagnostic Challenge

Article

Author: Pereira, Joana ; Neves da Silva, Luís ; Flores, Luis ; Teixeira, Sofia ; Ribeiro, Rui ; Araújo, Inês M ; Mendes, Francisco

Gastric variceal (GV) bleeding is a life-threatening complication of portal hypertension, most commonly associated with cirrhosis. However, non-cirrhotic portal hypertension (NCPH) is an important and under-recognized cause, with portosinusoidal vascular disorder (PSVD) being a key entity, particularly in patients exposed to chemotherapy. A 39-year-old man with a history of childhood neuroblastoma treated with dacarbazine, cyclophosphamide, doxorubicin, and vincristine presented with hematemesis and syncope. On admission, he was hypotensive and tachycardic. Laboratory tests revealed anemia (hemoglobin 6.9 g/dL), preserved liver function, and normal coagulation. Endoscopy showed a fundal GV with a "white nipple" sign. He received prompt vasoactive therapy, endoscopic cyanoacrylate injection, blood transfusion, and prophylaxis with ceftriaxone. Despite initial stabilization, bleeding recurred after terlipressin discontinuation, requiring a new endoscopic intervention. Common causes of cirrhosis were excluded. Imaging showed no parenchymal or vascular abnormalities. Elastography revealed normal liver stiffness (5.3 kPa) and elevated splenic stiffness (33.8 kPa). Hepatic angiography determined a portosystemic gradient of 15 mmHg. Liver biopsy demonstrated vascular changes consistent with PSVD. Extensive workup excluded other etiologies, leading to a final diagnosis of NCPH due to PSVD likely secondary to prior chemotherapy. The patient was started on a non-selective beta-blocker, with no further bleeding during follow-up. This case highlights the diagnostic and therapeutic challenges of GV bleeding in NCPH and underscores the importance of a systematic and multidisciplinary workup to identify PSVD. A detailed history, including prior chemotherapy exposure, is crucial for appropriate management.

165

News (Medical) associated with Terlipressin Acetate

27 Mar 2026

·www.prnewswire.com

Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at the SHM Converge

DUBLIN, March 27, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ® (terlipressin) will be shared at the Society of Hospital Medicine (SHM) Converge, taking place March 29-April 1, 2026. "We are pleased to share these findings with the medical community, as they help deepen our understanding of this challenging and rapidly progressive condition," said Dr. Marek Honczarenko, Executive Vice President and Chief Scientific Officer at Keenova. "Expanding the clinical evidence base is essential, and this analysis provides fresh insight into how clinicians are using TERLIVAZ in practice and how we can continue to support patients affected by HRS-AKI." TERLIVAZ is the first and only FDA‑approved therapy indicated to improve kidney function in adults with HRS‑AKI. Presentation Details Title: Real-World Utilization Patterns and Outcomes in Hospitalized U.S. Adults With Hepatorenal Syndrome-Acute Kidney Injury Treated with Terlipressin: A Retrospective Cohort Study Authors: A. Sidney Barritt IV, MD; Kavish R. Patidar, DO; Robert J. Wong, MD, MS; Xingyue Huang, PhD; Rachel Black, PharmD; Mary Panaccio, PhD; Jonathan Lilley, BA; Nisha Wadhwani, PhD; Rahul Rajkumar, MD, MPH; Christopher White, MD, MSPH About Hepatorenal Syndrome-Acute Kidney Injury Hepatorenal syndrome–acute kidney injury (HRS-AKI) is a life-threatening condition in adults with advanced liver disease that is marked by a rapid decline in kidney function1 and is associated with high morbidity and mortality.2 It is an acute medical emergency that requires hospitalization.3 A U.S. study based on national data revealed that the projected annual number of inpatients diagnosed with HRS has increased between 2018 and 2023, from 42,930 to 63,381.4 INDICATION TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. LIMITATION OF USE Patients with a serum creatinine >5 mg/dL are unlikely to experience benefit. IMPORTANT SAFETY INFORMATION WARNING: SERIOUS OR FATAL RESPIRATORY FAILURE TERLIVAZ may cause serious or fatal respiratory failure. Patients with volume overload or with acute-on-chronic liver failure (ACLF) Grade 3 are at increased risk. Assess oxygenation saturation (e.g., SpO 2 ) before initiating TERLIVAZ. Do not initiate TERLIVAZ in patients experiencing hypoxia (e.g., SpO 2 <90%) until oxygenation levels improve. Monitor patients for hypoxia using continuous pulse oximetry during treatment and discontinue TERLIVAZ if SpO 2 decreases below 90%. Contraindications TERLIVAZ is contraindicated: In patients experiencing hypoxia or worsening respiratory symptoms. In patients with ongoing coronary, peripheral, or mesenteric ischemia. Warnings and Precautions Serious or Fatal Respiratory Failure: Obtain baseline oxygen saturation and do not initiate TERLIVAZ in hypoxic patients. Monitor patients for changes in respiratory status using continuous pulse oximetry and regular clinical assessments. Discontinue TERLIVAZ in patients experiencing hypoxia or increased respiratory symptoms. Manage intravascular volume overload by reducing or discontinuing the administration of albumin and/or other fluids and through judicious use of diuretics. Temporarily interrupt, reduce, or discontinue TERLIVAZ treatment until patient volume status improves. Avoid use in patients with ACLF Grade 3 because they are at significant risk for respiratory failure. Ineligibility for Liver Transplant: TERLIVAZ-related adverse reactions (respiratory failure, ischemia) may make a patient ineligible for liver transplantation, if listed. For patients with high prioritization for liver transplantation (e.g., MELD ≥35), the benefits of TERLIVAZ may not outweigh its risks. Ischemic Events: TERLIVAZ may cause cardiac, cerebrovascular, peripheral, or mesenteric ischemia. Avoid use of TERLIVAZ in patients with a history of severe cardiovascular conditions or cerebrovascular or ischemic disease. Discontinue TERLIVAZ in patients who experience signs or symptoms suggestive of ischemic adverse reactions. Embryo-Fetal Toxicity: TERLIVAZ may cause fetal harm when administered to a pregnant woman. If TERLIVAZ is used during pregnancy, the patient should be informed of the potential risk to the fetus. Adverse Reactions The most common adverse reactions (≥10%) include abdominal pain, nausea, respiratory failure, diarrhea, and dyspnea. Please click here to see full Prescribing Information, including BOXED WARNING. About Keenova Keenova Therapeutics is a leading U.S.-focused branded therapeutics company that strives to help patients with rare or unaddressed conditions live happier and healthier lives. Keenova's rare disease capabilities underpin our diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. Headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania, and Wisconsin. To learn more, please visit . Keenova uses its website as a channel of distribution of important company information, such as press releases, investor presentations, and other financial information. It also uses its website to expedite public access to time-critical information regarding the Company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission ("SEC") disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website. Information Regarding Forward-Looking Statements This release contains forward-looking statements, including with regard to TERLIVAZ®, its potential to improve health and treatment outcomes, and its potential impact on patients. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the effects of emergence from bankruptcy; satisfaction of, and compliance with, regulatory and other requirements; actions of regulatory bodies and other governmental authorities; changes in laws and regulations; changes in market demand; issues with product quality, manufacturing or supply, or patient safety issues or adverse side effects or adverse reactions associated with TERLIVAZ; and other risks and uncertainties identified and described in more detail in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Keenova's most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q, its Registration Statement on Form S-4, as amended, filed with the SEC and other filings with the Securities and Exchange Commission (SEC), all of which are available on the SEC's website () and our website (). The forward-looking statements made herein speak only as of the date hereof and Keenova Therapeutics does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise, except as required by law. Given these uncertainties, one should not put undue reliance on any forward-looking statements. References Wong RJ, Balasubramanian J, Panaccio M, Huang X. Acute kidney injury and hepatorenal syndrome among hospitalized patients with chronic liver disease. JAMA Netw Open. 2025;8(5):e2511816. Loftus M, Brown RS Jr, El-Farra NS, Owen EJ, Reau N, Wadei HM, Bernstein D. Improving the management of hepatorenal syndrome–acute kidney injury using an updated guidance and a new treatment paradigm. Gastroenterol Hepatol (N Y). 2023;19(9):527-536. National Organization for Rare Disorders. Hepatorenal syndrome. Available at . Accessed March 17, 2026. Goyes M, et al. Increasing incidence, cost, and mortality of AKI and HRS in hospitalized patients with cirrhosis. JAMA Netw Open. 2025;8(5):e2511822. SOURCE Keenova Therapeutics 21% more press release views with Request a Demo

Drug Approval

17 Mar 2026

·endpoints.news

Pfizer's next-gen breast cancer data; Bristol Myers' PRMT5 candidate

Plus, news about Genentech, Mestag and BioVie: 📊 Pfizer says next-gen breast cancer drug succeeds in Phase 2: The company is developing a CDK4 inhibitor called atirmociclib as a successor to its breast cancer drug Ibrance, a CDK4/6 inhibitor. It said that atirmociclib plus the hormone therapy fulvestrant cut the risk of disease progression or death by 40% versus standard treatment options as part of a 264-patient trial. The study included patients with advanced HR-positive, HER2-negative breast cancer whose disease progressed after treatment with a CDK4/6 inhibitor. Pfizer did not share the median progression-free survival numbers from the Phase 2 study, noting detailed results will be reported at a future medical meeting. It did say that overall survival was not mature. Pfizer said that more than 90% of patients started on atirmociclib within three months of their last CDK4/6 inhibitor treatment. It is running a Phase 3 trial for atirmociclib as a first-line treatment for advanced HR-positive, HER2-negative breast cancer. That study is expected to bear results in 2029. — Lei Lei Wu 📊 Bristol Myers shares pancreatic cancer combo data on PRMT5 drug: Five of 11 pancreatic cancer patients saw their tumors shrink substantially following treatment with the experimental drug known as navlimetostat (previously BMS-986504) alongside chemotherapy, equating to an overall response rate of 46%. The median follow-up time was 6.6 months in the data cut shared at the ESMO Targeted Anticancer Therapies conference. Now, BMS is studying the regimen in a Phase 2/3 study for patients with previously untreated metastatic pancreatic cancer that bears a mutation called an MTAP deletion. The study is expected to be completed in 2029. — Lei Lei Wu 🛑 Genentech terminates Phase 2 trial in heart surgery-associated kidney injury: In an update to the trial’s webpage on the federal clinical trials database, the Roche-owned company said the Phase 2 is “unlikely to demonstrate a statistically significant clinical benefit.” Researchers were testing GDC-8264 in heart surgery patients who were susceptible to acute kidney injury within three months of the procedure. — Max Gelman 💰 Mestag closes $40M fundraise, announces C-suite additions: The cash will be used to fund Mestag’s first clinical trial, a Phase 1 study in cancer for MST-0312. Johnson & Johnson’s corporate venture arm participated in the round. The biotech also named Lindsey Rolfe as chief medical officer and Pascal Merchiers as its new chief development officer. — Max Gelman 💰 BioVie seeks up to $19.7M IPO for spinout: Option Therapeutics will move forward a reformulation of Mallinckrodt’s drug Terlivaz, approved in a kidney disorder, for a separate liver condition. The new company expects to receive $17 million in IPO funds but could net up to $19.7 million if all options are exercised, according to an SEC filing . — Max Gelman

Phase 2Phase 1IPOClinical ResultExecutive Change

17 Mar 2026

·www.fiercebiotech.com

BioVie plans $20M IPO for spinout tasked with developing liver disease drug

BioVie disclosed in 2024 that it was halting work on BIV201.\n BioVie is eyeing a $19.7 million IPO for a spinout focused on bringing a new formulation of an approved kidney failure drug to market as a potential treatment for liver disease.The plan is to offer 1.8 million shares of the spinout, called Option Therapeutics, priced between $10 and $12 apiece, according to a March 13 Securities and Exchange Commission (SEC) filing. Should the final price come in at the middle of this range, BioVie expects Option to rake in $17 million in net proceeds for the IPO—rising to $19.7 million if underwriters fully take up their option to buy an additional 272,727 shares at the same price.After the IPO—for which a date has yet to be set—BioVie will still own at least 60% of Option, meaning the company has the final say in electing Option’s directors.Option will be focused on taking forward an investigational infusion treatment called BIV201. The vasopressin V1 receptor agonist is made of terlipressin acetate, an injectable form of which is marketed by Mallinckrodt Pharmaceuticals under the name Terlivaz to improve kidney function for adults with hepatorenal syndrome. BioVie had previously been evaluating BIV201 for ascites, a common complication of liver cirrhosis. There are currently no approved treatments specifically for the condition.With about 190,000 patients hospitalized each year in the U.S. with cirrhosis and ascites, BioVie has estimated that the potential market for BIV201 could top $2.3 billion. But, despite having labeled BIV201 its “most de-risked program,” BioVie disclosed in 2024 that it was halting work on the asset, explaining that “unfortunately [it] is a program that will take two years to complete.”At the time, BioVie CEO Cuong Do said the biotech “look[ed] forward to partnering this program with a company interested in developing the first potential treatment for ascites and related complications potentially at an earlier stage of cirrhosis.” Now, it’s been decided that the vehicle to take BIV201 forward will be Option. In Friday’s SEC filing, BioVie reaffirmed that it had already received clearance from the FDA to begin a phase 3 study in adults with decompensated liver cirrhosis and ascites who have recently recovered from, or are recovering from, acute kidney injury. The only thing delaying Option is sourcing the necessary funds.After a lull of biotech IPOs in 2025, Option could soon be joining a growing list of drug developers voicing an interest in the public markets. CEOs of companies that already made the leap this year told Fierce they had detected a positive change in sentiment toward biotech IPOs in recent months.

IPOPhase 3

100 Deals associated with Terlipressin Acetate

External Link

KEGG	Wiki	ATC	Drug Bank
D08571	Terlipressin Acetate	H01BA04	DB02638

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bleeding esophageal varices	Australia	Ferring Pharmaceuticals Pty Ltd.	14 May 2012
Hepatorenal Syndrome	Australia	Ferring Pharmaceuticals Pty Ltd.	14 May 2012
Hemorrhage	China	Ferring GmbH	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Ascites	Phase 3	United States	BioVie, Inc.	19 Sep 2023
Decompensated cirrhosis of liver	Phase 2	United States	BioVie, Inc.	17 Jun 2021
Fibrosis	Phase 2	United States	BioVie, Inc.	15 Jul 2017
Hepatic ascites	Phase 2	United States	BioVie, Inc.	15 Jul 2017
Liver Cirrhosis	Phase 2	United States	BioVie, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01143246 \| NCT00089570 \| NCT02770716 (OT-0401, Pubmed \| Aliment Pharmacol Ther)	Phase 3	Hepatorenal Syndrome	598	Terlipressin	puerhhockx(vqeqxcmfml) = pdzjttsncc fhfeyhrbds (zcbqvygkvo ) View more	Positive	01 Dec 2025
				Placebo	puerhhockx(vqeqxcmfml) = yahrqepotf fhfeyhrbds (zcbqvygkvo ) View more
NCT01143246 \| NCT02770716 (REVERSE, PRNewswire) Manual	Phase 3	Hepatorenal Syndrome	-	TERLIVAZ	ednbpjomod(wzztbkczge) = shetgyyyqr jophugbizz (mdavwovxvy ) View more	Positive	26 Oct 2024
				Placebo	ednbpjomod(wzztbkczge) = yhoxjmzdcy jophugbizz (mdavwovxvy ) View more
ASN2024	Not Applicable	Liver Diseases	110	Terlipressin	yxhewuskzh(idctsayunu) = osfxcrndvj snmrliefer (hgdncmxdlx ) View more	Positive	26 Oct 2024
NCT04460560 (INFUSE, CTgov)	Phase 3	Myoclonic Epilepsies, Progressive \| Hepatorenal Syndrome	50	Terlipressin (Open-label Terlipressin)	todxoztqnz = yzdpmphfxo ysqeyzejde (kdcgfyflxh, sxydxpugnz - moaoxzcoxr) View more	-	09 Oct 2024
				Terlipressin (Open-Label Terlipressin)	vtijbhnqfz(krxkdjissp) = skeymfmvlv ilrtqwgkge (wvyclnvxxk, qwduktrkrj - fyxinobhpf) View more
EASL2024 Manual	Phase 3	Hepatorenal Syndrome	83	Terlipressin (MAP <65 mm Hg)	ukipwtafpd(xloacypnfv) = ehhjixgqpd nkvttwjpwj (xaxfxtkbjb ) View more	Positive	01 Jun 2024
				Placebo (MAP <65 mm Hg)	ukipwtafpd(xloacypnfv) = xqvortguuo nkvttwjpwj (xaxfxtkbjb ) View more
EASL2024 Manual	Not Applicable	Hepatorenal Syndrome	-	terlipressin	cbqjgbycmi(quonuofisr) = usrpolwjph mcwybbxpga (vcxvvrpidp ) View more	Positive	01 Jun 2024
EASL2024 Manual	Phase 3	Hepatitis, Alcoholic \| Hepatorenal Syndrome	141	Terlipressin	csuvqhqveq(kqamjqbkxd) = uxkctaxotr kjujmtpzvi (afxbhbzlqp ) View more	Positive	01 Jun 2024
				Placebo	csuvqhqveq(kqamjqbkxd) = owhuyvlmjg kjujmtpzvi (afxbhbzlqp ) View more
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	Not Applicable	-	-	Terlipressin	lokpvytoog(guzxoxqhsm) = cmdwpihzzl dapqtjtiph (ihlqebymzl ) View more	-	18 May 2024
				Placebo	lokpvytoog(guzxoxqhsm) = fxpemmunkd dapqtjtiph (ihlqebymzl ) View more
DDW 12024 \| DDW 22024 \| DDW 32024 \| DDW 42024	Not Applicable	Acute Kidney Injury	-	Terlipressin	wrrcgprbwn(wdcszrvqrq) = A dose interruption due to AEs was needed for 7% of pts in both treatment groups (terli: 14/200; pbo: 7/99) rlpjybubal (cbmtkjltvr ) View more	-	18 May 2024
				Placebo
NCT02770716 (CONFIRM, PRNewswire) Manual	Phase 3	Hepatorenal Syndrome	117	TERLIVAZ	iviioeixfm(ezlpmiijbe) = vmwlaqinys hcecgshyed (xlquhreevr ) View more	Positive	22 Jan 2024
				Placebo	iviioeixfm(ezlpmiijbe) = emtftmtvnj hcecgshyed (xlquhreevr ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis